Filing Details
- Accession Number:
- 0001493152-22-007206
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-17 21:27:46
- Reporting Period:
- 2022-03-15
- Accepted Time:
- 2022-03-17 21:27:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1642380 | Oncocyte Corp | OCX | In Vitro & In Vivo Diagnostic Substances (2835) | 271041563 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1807104 | Gisela Paulsen | 15 Cushing Irvine CA 92618 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, No Par Value | Acquisiton | 2022-03-17 | 16,500 | $1.20 | 16,500 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option to Purchase Common Stock | Acquisiton | 2022-03-15 | 125,000 | $0.00 | 125,000 | $1.15 |
| Common Stock | Option to Purchase Common Stock | Acquisiton | 2022-03-15 | 125,000 | $0.00 | 125,000 | $1.15 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 125,000 | 2032-03-15 | No | 4 | A | Direct | |
| 125,000 | 2032-03-15 | No | 4 | A | Direct |
Footnotes
- The price of $1.198 per share represents a weighted average of prices ranging from $1.180 to $1.200 per share. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price
- 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
- Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
Billionaire Hedge Funds
